My Profile

Search abstracts

Lewis Sheiner

Stockholm, Sweden
 Register / submit abstract

Montreux, Switzerland

Budapest, Hungary

Lisboa, Portugal

Hersonissos, Crete, Greece

Alicante, Spain

Glasgow, Scotland

Venice, Italy

Athens, Greece

Berlin, Germany

St. Petersburg, Russia

Marseille, France

København, Denmark

Brugge/Bruges, Belgium

Pamplona, Spain

Uppsala, Sweden

Verona, Italy

Paris, France

Basel, Switzerland

Salamanca, Spain

Saintes, France

Wuppertal, Germany

Glasgow, Scotland

Sandwich, UK

Frankfurt, Germany

Greenford, UK

Paris, France

Basel, Switzerland

   Stockholm, Sweden

III-01 Clémence Rigaux
An approach for reducing the sample sizes of pediatric trials in Type 2 Diabetes Mellitus: longitudinal analysis versus standard analyses
Thursday 09:55-11:20
III-02 Matthew Riggs
M-EASE-1: A Modelling and simulation study conducted to further characterize the efficacy of low-dose Empagliflozin as Adjunctive to inSulin thErapy (M-EASE) in Type 1 Diabetes Mellitus
Thursday 09:55-11:20
III-03 François Riglet
Bayesian individual dynamic predictions of biomarkers and risk of event in joint modelling (with uncertainty): a comparison between Stan, Monolix and NONMEM
Thursday 09:55-11:20
III-04 Christer Rimmler
Evaluating the Influence of Cardiopulmonary Bypass on the Pharmacokinetics of Cefuroxime using PBPK and PopPK Models
Thursday 09:55-11:20
III-05 Viktor Rognås
Bounded Integer approach to model time-varying SOFA scores from patients with carbapenem resistant infections
Thursday 09:55-11:20
III-06 Federico Romano
Predictive performance of a parasite growth dynamics model for the evaluation of anti-malarial drugs: a case study with mefloquine
Thursday 09:55-11:20
III-07 Daniel Röshammar
Assessment of expected drug exposure relative maximum safety limits in early phase studies
Thursday 09:55-11:20
III-08 Ryosuke Shimizu
Quantitative systems pharmacology modeling of thrombopoiesis and platelet life-cycle, and application for thrombocytopenia
Thursday 09:55-11:20
III-10 Tomohisa Saito
The evaluation of a population pharmacokinetic model of Tofogliflozin with the data from healthy volunteers and T2DM patients
Thursday 09:55-11:20
III-11 Louis Sandra
A population pharmacokinetic model for propofol in (pre)term neonates and infants independently accounting for size, gestational age (GA) and postnatal age (PNA).
Thursday 09:55-11:20
III-12 Marina Savelieva
Modeling decline in cognition to decline in function in Alzheimer’s disease
Thursday 09:55-11:20
III-13 Annika Schneider
A PBPK approach for simulating the effect of liver cirrhosis on drug PK
Thursday 09:55-11:20
III-14 Rik Schoemaker
Performance of the SAEM and FOCEI algorithms in the open-source non-linear mixed effect modelling tool nlmixr
Thursday 09:55-11:20
III-15 Jérémy Seurat
Comparison of Phase I combination therapy designs by clinical trial simulations to evaluate early tumor shrinkage
Thursday 09:55-11:20
III-16 Dmitry Shchelokov
Physiologically based pharmacokinetic modeling of anti-PD-1 therapeutic antibodies
Thursday 09:55-11:20
III-17 Soyoung Shin
Novel population approach to establish in vitro-in vivo correlation for drugs with site-dependent absorption
Thursday 09:55-11:20
III-18 Christian Siebel
Development of an adaptive dosing approach for doxorubicin in paediatric cancer patients
Thursday 09:55-11:20
III-19 Iryna Sihinevich
Mathematical Modeling of Glucose Homeostasis in Morbidly Obese Diabetic Patients Undergoing Roux-en-Y Gastric Bypass Surgery: An IMI DIRECT Study
Thursday 09:55-11:20
III-20 Florian Simon
A generic PBPK model for predicting the impact of inflammation on midazolam pharmacokinetics
Thursday 09:55-11:20
III-21 Noppaket Singkham
Pharmacogenetics-Based Population Pharmacokinetic Analysis for Dosing Optimization of Ritonavir-Boosted Atazanavir in Thai adult HIV-Infected Patients
Thursday 09:55-11:20
III-22 Jaydeep Sinha
Extension of the Janmahasatian fat-free mass model to account for ethnicity-related bias
Thursday 09:55-11:20
III-23 Erik Sjögren
A PBPK Framework to Predict Drug Exposure in Malnourished Children
Thursday 09:55-11:20
III-24 Eunjung Song
Selection of optimal study design based on the bioequivalence simulation study in highly variable drugs
Thursday 09:55-11:20
III-25 Elena Soto
Population Pharmacokinetic (PopPK) Modelling and Simulation of Pregabalin to Support Dose Recommendation in Paediatric Patients 1 month to <4 years of Age with Partial Onset Seizures (POS)
Thursday 09:55-11:20
III-26 Tomás Sou
Translational PK and PKPD modelling for the analysis of preclinical in-vitro and in-vivo studies to predict efficacious human dose of apramycin
Thursday 09:55-11:20
III-27 Viktoria Stachanow
Does dried blood spot data enrich our understanding of hydrocortisone pharmacokinetics in paediatric patients with adrenal insufficiency?
Thursday 09:55-11:20
III-28 Felix Stader
Physiologically based pharmacokinetic modelling to identify pharmacokinetic parameters driving age-related changes in drug exposure in the elderly
Thursday 09:55-11:20
III-29 Gabriel Stillemans
Simultaneous population pharmacokinetic modeling of darunavir and cobicistat in a cohort of HIV patients
Thursday 09:55-11:20
III-30 Mark Stroh
Translation and Mechanistic Corroboration of the Preliminary Clinical Pharmacokinetics and Pharmacodynamics of a Masked, Tumor‑Activated anti-PD-L1 Antibody with Systems Pharmacology
Thursday 09:55-11:20
III-31 Herbert Struemper
Population Pharmacokinetics of Belimumab Administered Intravenously in Children with Systemic Lupus Erythematosus
Thursday 09:55-11:20
III-32 Sabine Stuebler
Systems biology model of the mucosal immune system
Thursday 09:55-11:20
III-33 Suein Choi
contribution of trough concentration data for the evaluation of multiple-dose pharmacokinetics
Thursday 09:55-11:20
III-34 Jesper Sundell
Pharmacokinetic variability of isoniazid, and its two major metabolites in patients co-infected with tuberculosis and HIV
Thursday 09:55-11:20
III-35 Budi Octasari Susanto
Translational Model-Informed Selection of Tuberculosis Drug Combination Regimens for Early Clinical Development
Thursday 09:55-11:20
III-36 Hadi Taghvafard
Modeling (a)symmetry of concentration-effect curves
Thursday 09:55-11:20
III-37 Hiroyuki Takita
The dynamics of pharmacological effects aimed at gut wall: A framework for a nested-target-within-enterocyte (NTWE) model that accounts for turnover of target and cell
Thursday 09:55-11:20
III-38 Lénaïg Tanneau
Evaluating potential link between liver enzyme abnormalities and bedaquiline exposure in multi-drug resistant tuberculosis patients
Thursday 09:55-11:20
III-39 Joel Tarning
Severe acute malnutrition results in lower exposure in children treated with artemether-lumefantrine for uncomplicated malaria
Thursday 09:55-11:20
III-40 David Ternant
Revisiting target-mediated elimination of therapeutic antibodies: the irreversible binding approximation
Thursday 09:55-11:20
III-41 Mita Thapar
Population pharmacokinetic analysis of MSB11022 following administration in healthy subjects and rheumatoid arthritis patients.
Thursday 09:55-11:20
III-42 Anders Thorsted
Model-based translation from piglets to healthy volunteers: Prediction of TNF-α and IL-6 time-courses in human endotoxin challenge studies
Thursday 09:55-11:20
III-43 Tjokosela Tikiso
A pooled analysis of abacavir pharmacokinetics in HIV-infected African children: the effect of age, malnutrition, and common concomitant co-medications.
Thursday 09:55-11:20
III-44 Pauline Traynard
New library of double absorptions PK models for the MonolixSuite, application to veralipride pharmacokinetics
Thursday 09:55-11:20
III-45 Carlos Traynor
Towards personalised medicine in Non-Small Cell Lung Cancer: design of a forecasting model of disease-progression to overall survival.
Thursday 09:55-11:20
III-46 Iñaki F. Trocóniz
A modelling platform for onco-immunological drugs in early drug development
Thursday 09:55-11:20
III-47 Denise Tuerk
Physiologically-based pharmacokinetic modeling of the CYP2C8 perpetrator trimethoprim
Thursday 09:55-11:20
III-48 Sami Ullah
Population pharmacokinetics of cefepime in critically ill patients with and without impaired renal function
Thursday 09:55-11:20
III-49 Parth Upadhyay
Exploring the Relationship Between Midazolam Concentrations And Level Of Sedation In Critically-Ill Mechanically Ventilated Children Using Markov Modelling
Thursday 09:55-11:20
III-50 David Uster
Predictive performance of population pharmacokinetic models for Bayesian forecasting of coagulation factor VIII in hemophilia A
Thursday 09:55-11:20
III-51 Pavan Vaddady
Application of Bayesian Methodology to Inform Imipenem/Relebactam Pediatric Study Design
Thursday 09:55-11:20
III-52 Cristina Vaghi
Population modeling of tumor growth curves, the reduced Gompertz model and prediction of the age of a tumor
Thursday 09:55-11:20
III-53 Stijn van Beek
Population Pharmacokinetics and Model-Informed Precision Dosing of Isoniazid in Tuberculosis Patients
Thursday 09:55-11:20
III-54 Arthur Van De Vyver
in vitro PK/PD modeling of immunological synapse-based tumor cell killing and immune activation to predict in vitro efficacy of T-Cell Bispecifics.
Thursday 09:55-11:20
III-55 Louvina van der Laan
Pharmacokinetics and drug-drug interactions of lamivudine and abacavir administered with antituberculosis drugs in HIV-infected children with multidrug-resistant tuberculosis
Thursday 09:55-11:20
III-56 Jan-Stefan van der Walt
A Population Pharmacokinetic Analysis to Explore the Effect of Hepatic Impairment on Abemaciclib Pharmacokinetics
Thursday 09:55-11:20
III-57 Tamara van Donge
Methadone dosing strategies in preterm neonates can be simplified
Thursday 09:55-11:20
III-58 Rob van Wijk
Nanoscale pharmacokinetics and pharmacodynamics of isoniazid treatment of tuberculosis in zebrafish larvae
Thursday 09:55-11:20
III-59 Filippo Venezia
Preclinical Pharmacokinetic/Pharmacodynamic modeling to evaluate combination efficacy and the modification effect of oncology compounds with anti-angiogenic drugs (Sunitinib, Axitinib)
Thursday 09:55-11:20
III-60 Diego Vera
Pharmacokinetic-Pharmacodynamic model for Acute Intermittent Porphyria in porphyric mice treated with a new recombinant PBGD protein
Thursday 09:55-11:20
III-61 Luka Verrest
Exploring variability in paromomycin pharmacokinetics in East African visceral leishmaniasis patients
Thursday 09:55-11:20
III-62 Ludwig Vincent
How to improve the accuracy of Drug-Drug Interaction risk prediction for Mechanism Based Inhibitors
Thursday 09:55-11:20
III-63 Janet Wade
Population PK analysis with full and reduced covariate models for Sym004, an antibody mixture targeting EGFR
Thursday 09:55-11:20
III-64 Ulrika Wählby Hamrén
Longitudinal FEV1 and exacerbation risk in COPD: Quantifying the association using joint modelling
Thursday 09:55-11:20
III-65 Wenyi Wang
Physiological Response to Endotoxin Infusion in the Piglet: Modelling of changes in hemodynamic outcomes
Thursday 09:55-11:20
III-66 Shijun Wang
Comparison of approaches for estimating covariate effects in full random effects models
Thursday 09:55-11:20
III-67 Zhigang Wang
A Pharmacokinetic-Pharmacodynamic model built on in vitro data predict the antibacterial effect of polymyxin B against Klebsiella Pneumoniae in vivo
Thursday 09:55-11:20
III-68 Linda Wanika
Investigating the relationship between Lactate Dehydrogenase and the occurrence of Chronic Lower Respiratory Diseases
Thursday 09:55-11:20
III-69 Shayne Watson
Development and Evaluation of a Human Physiologically Based Pharmacokinetic Model to Assess a Mitigation Strategy for Risks Associated with Novel Monoclonal Antibodies
Thursday 09:55-11:20
III-70 Sebastian Weber
Qualifying drug dosing regimens in pediatrics using Gaussian Processes
Thursday 09:55-11:20
III-71 Ferdinand Weinelt
A joint pharmacokinetic model of piperacillin/tazobactam including mechanistic renal clearance in critically ill patients
Thursday 09:55-11:20
III-72 Gustaf Wellhagen
Modelling UACR as a clinical endpoint
Thursday 09:55-11:20
III-73 Quirin Werthner
Network-based mathematical modelling of HPV transmission and cervical cancer in Germany.
Thursday 09:55-11:20
III-74 Sebastian Wicha
TDMxR: an open-source package for model-based therapeutic drug monitoring in R
Thursday 09:55-11:20
III-75 Mélanie Wilbaux
Projecting MIW815 (ADU-S100) human tumor PK after intra-tumoral injection using a translational modeling approach combining pre-clinical and clinical data
Thursday 09:55-11:20
III-76 Justin Wilkins
Population Pharmacokinetics analysis of M5717, a novel antimalarial agent
Thursday 09:55-11:20
III-77 Francis Williams Ojara
Time-to-event analysis framework to evaluate the impact of paclitaxel exposure on peripheral neuropathy in patients with advanced non-small cell lung cancer receiving first-line chemotherapy
Thursday 09:55-11:20
III-78 Jan-Georg Wojtyniak
Physiologically-based Pharmaokinetic Modelling of Metoprolol Drug-Drug-Gene Interactions with Paroxetine and CYP2D6
Thursday 09:55-11:20
III-79 Dan Wright
Kinetic-pharmacodynamic models in the setting of non-linear drug elimination
Thursday 09:55-11:20
III-80 Li Xia
A Physiologically-Based Pharmacokinetic Model of Voriconazole
Thursday 09:55-11:20
III-81 Rujia Xie
Pharmacokinetic-Pharmacodynamic Analysis of Anidulafungin in Pediatric and Adult Patients with Invasive Fungal Infections
Thursday 09:55-11:20
III-82 Estelle Yau
A global sensitivity analysis of the Rodgers and Rowland equations predicting drug distribution in PBPK models
Thursday 09:55-11:20
III-83 Anyue Yin
Population pharmacokinetics and pharmacogenetics analysis of mitotane in adrenocortical carcinoma patients towards individualized dosing
Thursday 09:55-11:20
III-84 Jinqiu Yin
Pharmacokinetic-pharmacodynamic modeling of colistin against Pseudomonas aeruginosa-associated biofilm infections
Thursday 09:55-11:20
III-85 Sirin Yonucu
Explaining inter-species differences to anti-PDL1 cancer immunotherapy using a translational quantitative systems pharmacology approach
Thursday 09:55-11:20
III-86 Jurij Zdovc
Population pharmacokinetic modeling of cisplatin in patients with small cell lung cancer using informative priors
Thursday 09:55-11:20
III-87 Yang Zhang
Ways to improve the efficiency of pharmacometric model implemented in R using deSovle – an example with a PK model for ADC
Thursday 09:55-11:20
III-88 Chenyan Zhao
Colistin to overcome resistance to ciprofloxacin - Quantifying combined effects of colistin and ciprofloxacin against four E. coli strains with different ciprofloxacin susceptibility in an in silico PKPD model
Thursday 09:55-11:20
III-89 Xuan Zhou
Model-Based Estimation of Probability of Pharmacological Success for CNS Compounds
Thursday 09:55-11:20
III-90 Tom Zwart
Population pharmacokinetics and limited sampling of iohexol as a renal function marker
Thursday 09:55-11:20